Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?
This review systematically maps the global clinical trial landscape for chronic myeloid leukemia (CML), highlighting the predominant use of tyrosine‑kinase inhibitors (TKIs), the persistent challenges of resistance and relapse, and the emerging promise of combination therapies such as Venetoclax with TKIs.
CML patients treated with TKIs now enjoy near‑normal life expectancy, yet 20–30 % still experience suboptimal responses, drug resistance, or disease progression. Understanding the evolving trial landscape is essential to guide future therapeutic strategies, improve patient outcomes, and address unmet needs such as equity across diverse populations and management of early‑phase disease.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia